API

Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.2mg)

Drug classification

Oral antidiabetic; sulfonylurea (glimepiride), biguanide (metformin), alpha-glucosidase inhibitor (voglibose).

Dosage form

Film-coated, sustained-release oral tablet.

API strength per dosage

Dose

Glycomet Trio 2 Tablet SR is typically taken once daily with meals. Dose adjustments may be needed based on glycemic response. Not recommended in severe renal or hepatic impairment. Safety and efficacy in children have not been established. Always individualize dosing and monitor renal function regularly. Consult product literature for full prescribing information.

Mechanism of action

Glimepiride stimulates pancreatic β-cell insulin release (blocks ATP-sensitive K⁺ channels), metformin decreases hepatic gluconeogenesis and increases insulin sensitivity (activates AMP-activated protein kinase), and voglibose inhibits intestinal α-glucosidase, delaying carbohydrate absorption; together, they lower blood glucose by enhancing insulin action, reducing glucose production, and slowing glucose absorption.

Indications

Treatment of Type 2 diabetes mellitus

Side effects

Nausea Diarrhea Abdominal pain Hypoglycemia low blood glucose level

Pregnancy category

Safety in pregnancy is not established; use only if clearly needed and potential benefits outweigh risks. Consult a healthcare provider before use.

Precautions

Monitor blood glucose, renal and hepatic function, signs of hypoglycemia, gastrointestinal tolerance, vitamin B12 levels, risk of lactic acidosis, avoid in severe renal/hepatic impairment, caution in elderly, monitor for allergic reactions, assess for drug interactions, ensure adequate hydration, avoid excessive alcohol intake.

Contraindications

Hypersensitivity to glimepiride, metformin, voglibose, or excipients, diabetic ketoacidosis, severe renal impairment, acute or chronic metabolic acidosis, severe hepatic dysfunction, gastrointestinal obstruction, inflammatory bowel disease, pregnancy, lactation.